logo

For the Inventor, By the Inventor

Lund, Sweden

Pavol Zlatoidsky

This inventor holds 10 USPTO granted patents and 2 published patent applications and 3 EPO patents. Top assignee: Astrazeneca Ab. Active years: 2006-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Pavol Zlatoidsky. Retrieved from https://idiyas.com/inventor/pavol-zlatoidsky

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 


Average Co-Inventor Count = 5.3

ph-index = 4

Forward Citations = 63(Granted Patents)


Location History:

  • Lund, SE (2006 - 2012)
  • Mölndal, SE (2020)

Company Filing History:

goldMedal10 out of 1,534 
 
Astrazeneca Ab
 patents

Years Active: 2006-2020

Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents
1. 10858355 - Inhibitors of phosphatidylinositol 3-kinase gamma (2020-12-08),
2. 8153673 - Metalloproteinase inhibitors (2012-04-10),
3. 7754750 - Metalloproteinase inhibitors (2010-07-13),
4. 7700604 - Hydantoin derivatives as metalloproteinase inhibitors (2010-04-20),
5. 7666892 - Metalloproteinase inhibitors (2010-02-23),
6. 7655664 - Hydantoin derivatives as metalloproteinase inhibitors (2010-02-02),
7. 7625934 - Metalloproteinase inhibitors (2009-12-01),
8. 7427631 - Metalloproteinase inhibitors (2008-09-23),
9. 7368465 - Metalloproteinase inhibitors (2008-05-06),
10. 7132434 - Metalloproteinase inhibitors (2006-11-07),

Title: The Innovative Contributions of Pavol Zlatoidsky

Introduction

Pavol Zlatoidsky is a prominent inventor based in Lund, Sweden. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target critical biological pathways. With a total of 10 patents to his name, Zlatoidsky's work has the potential to impact the treatment of various clinical conditions.

Latest Patents

Among his latest patents, Zlatoidsky has developed inhibitors of phosphatidylinositol 3-kinase gamma. These novel compounds, including their pharmaceutically acceptable salts, are designed to inhibit PI3Kγ activity. Their utility lies in treating and preventing respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Additionally, he has worked on metalloproteinase inhibitors, specifically compounds that inhibit MMP12, showcasing his diverse expertise in medicinal chemistry.

Career Highlights

Zlatoidsky is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. His role at AstraZeneca allows him to collaborate with other experts in the field and contribute to groundbreaking research and development efforts. His innovative approach to drug discovery has positioned him as a key figure in the pharmaceutical industry.

Collaborations

Throughout his career, Zlatoidsky has collaborated with notable colleagues, including Michael Lundkvist and Anders Eriksson. These partnerships have fostered an environment of innovation and have led to the successful development of various therapeutic compounds.

Conclusion

Pavol Zlatoidsky's contributions to the field of pharmaceuticals are noteworthy, with a focus on developing innovative compounds for treating serious health conditions. His work continues to influence the landscape of drug development and offers hope for improved therapies in the future.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…